Table 1 Table highlighting polyamine metabolism targeting inhibitors tested in preclinical and/or clinical studies.

PA, polyamine.

Preclinical studies
InhibitorTargetCancerReference
DFMOODC1Prostate cancer(101, 102)
Pancreatic cancer(103)
Breast cancer(104, 105)
Colon cancer(106)
Neuroblastoma(107, 108)
Live cancer(109)
MGBCPAMD1Prostate cancer(102)
Leukemia(110)
Osteosarcoma(111)
Melanoma(112)
SAM486A (CGP48664)AMD1Bladder cancer, melanoma(113)
Neuroblastoma(107)
ORI 1202*PA transporterBreast cancer(105)
Prostate cancer(101)
BENSpm/DENSpm# [N (1),N (11)bis(ethyl)norspermine]PA analogBreast cancer(114)
PG11047/CGC-11047#PA analogLung cancer(115)
Prostate and lung cancer(116)
Pediatric tumors(117)
SL11144/ CGC-11144PA analogBreast cancer(118)
Clinical trials
InhibitorTargetCancer typeReference
DFMOODC1Prostate cancer(119)
Lung and colon cancer(120)
MGBCPAMD1Prostate cancer(119)
SAM486A (CGP48664)AMD1Solid tumors(18, 19, 121, 122)
Non-Hodgkin’s lymphoma(121, 123)
BENSpm/DENSpm# [N1,N11-bis(ethyl)norspermine]PA analogSolid tumors(124)
Non–small cell lung cancer(125)
Metastatic breast cancer(126)
DEHSPM (N1,N14-diethyl homospermine)PA analogSolid tumors(127)
PG11047/CGC-11047#PA analogSolid tumorswww.clinicaltrials.gov, NCT00705653
Solid tumors and lymphomawww.clinicaltrials.gov, NCT00705874

*In combination with other inhibitors.

#As a single agent and in combination with chemotherapy.